{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276019","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.715935+00:00","generated_at":"2026-05-16T21:30:45.891490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen reports Q3 net loss of $18.0M; 53.7% splicing correction in DM1 Phase 1","bullets":["FREEDOM-DM1 15 mg/kg showed mean splicing correction of 53.7%, highest reported in DM1 patients.","All patients in FREEDOM2 5 mg/kg cohort enrolled; topline data expected Q1 2026.","Closed $115M public offering in Sept 2025; cash runway extended into H2 2027.","Net loss $18.0M ($0.52/sh) vs $21.4M ($0.66/sh) in Q3 2024; cash $163.7M at Sept 30.","R&D expense $13.4M down from $17.7M YoY; G&A flat at $5.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276019","json":"https://secwatch.observer/filing/0001193125-25-276019.json","markdown":"https://secwatch.observer/filing/0001193125-25-276019.md","text":"https://secwatch.observer/filing/0001193125-25-276019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/0001193125-25-276019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/pepg-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:30:45.891490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}